Share on StockTwits

BTG plc (LON:BTG)‘s stock had its “buy” rating reaffirmed by investment analysts at Panmure Gordon in a note issued to investors on Wednesday. They currently have a GBX 670 ($11.47) price objective on the stock. Panmure Gordon’s price target would indicate a potential upside of 7.03% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at FinnCap reiterated a “sell” rating on shares of BTG plc in a research note on Wednesday. They now have a GBX 345 ($5.91) price target on the stock. Separately, analysts at Investec raised their price target on shares of BTG plc from GBX 723 ($12.38) to GBX 728 ($12.46) in a research note on Wednesday, July 2nd. They now have a “buy” rating on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of BTG plc in a research note on Wednesday, July 2nd. They now have a GBX 655 ($11.21) price target on the stock. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of GBX 536.88 ($9.19).

BTG plc (LON:BTG) traded up 0.08% on Wednesday, hitting GBX 626.00. The stock had a trading volume of 444,528 shares. BTG plc has a one year low of GBX 363.00 and a one year high of GBX 665.00. The stock’s 50-day moving average is GBX 618.5 and its 200-day moving average is GBX 581.8. The company’s market cap is £2.259 billion.

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.